Vertex Pharmaceuticals (VRTX) Interest Coverage Ratio (2009 - 2026)
Vertex Pharmaceuticals (VRTX) posted quarterly Interest Coverage Ratio of 2.71 for Q1 2026, up 53.59% year-over-year from 1.76 in Q1 2025, and down 88.08% quarter-over-quarter from 22.71 in Q4 2025.
Vertex Pharmaceuticals (VRTX) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Vertex Pharmaceuticals' Interest Coverage Ratio history runs 18 years deep, the most recent figure standing at 2.71 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 53.59% year-over-year to 2.71; the TTM figure through Mar 2026 stood at 11.14 (up 636.27% YoY), while the FY2025 annual figure was 9.56, up 1501.17% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 2.71, down from 22.71 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 89.86 in Q4 2023, with the low at 11.36 in Q2 2024.
- The 5-year median for Interest Coverage Ratio is 4.1 (2023), against an average of 15.73.
- The sharpest annual moves came in 2022 and 2024: Interest Coverage Ratio soared 1798.73% in 2022, then sank 377.22% in 2024.
- Vertex Pharmaceuticals' Interest Coverage Ratio stood at 75.44 in 2022, then climbed by 19.12% to 89.86 in 2023, then slumped by 53.4% to 41.88 in 2024, then slumped by 45.77% to 22.71 in 2025, then slumped by 88.08% to 2.71 in 2026.
- Business Quant data shows VRTX's Interest Coverage Ratio at 2.71 in Q1 2026, 22.71 in Q4 2025, and 2.81 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -55.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.84 |
| Mar 31, 2026 | 2.71 |
| Dec 31, 2025 | 22.71 |
| Sep 30, 2025 | 2.81 |
| Jun 30, 2025 | 2.79 |
| Mar 31, 2025 | 1.76 |
| Dec 31, 2024 | 41.88 |
| Sep 30, 2024 | 0.40 |
| Jun 30, 2024 | -11.36 |
| Mar 31, 2024 | 3.78 |
| Dec 31, 2023 | 89.86 |
| Sep 30, 2023 | 4.23 |
| Jun 30, 2023 | 4.10 |
| Mar 31, 2023 | 3.35 |
| Dec 31, 2022 | 75.44 |
| Sep 30, 2022 | 7.78 |
| Jun 30, 2022 | 7.62 |
| Mar 31, 2022 | 7.58 |
| Dec 31, 2021 | 64.54 |
| Sep 30, 2021 | 11.85 |